

Amendments to the Claims

1. (currently amended) A formulation comprising olanzapine pamoate monohydrate as an active ingredient and one or more carriers selected from the group consisting of an oleaginous carrier or cholesterol microsphere carrier wherein said formulation has a prolonged sustained release of greater than 7 days and up to 30 days, and a burst release of less than 15% of the active ingredient.

2. (cancelled)

3. (original) A formulation as claimed in Claim 1 wherein said carrier is oleaginous.

4. (cancelled)

5. (cancelled)

6. (currently amended) A formulation as claimed by Claim ~~1~~ 2 wherein the formulation further comprises one or more pharmaceutically acceptable excipients.

7. (original) A formulation as claimed by Claim 6 wherein the pharmaceutically acceptable excipient is selected from the group consisting of a gelling agent and an antihydration agent.

8. (cancelled)

9. (cancelled)

10. (original) A formulation as claimed in Claim 1 wherein the carrier is a cholesterol microparticle.

11. (original) A formulation as claimed in Claim 10 wherein the microparticle is a microsphere.

12. (original) A formulation as claimed in Claim 10 wherein the cholesterol is selected from the group consisting of cholesterol, cholesterol palmitate, cholesterol oleate, cholesterol stearate, and cholesterol hemisuccinate.

13. (original) A formulation as claimed in Claim 10 wherein the microspheres have a particle size of from 20 to 500 μ m.

14. (original) A formulation as claimed in Claim 13 wherein the particle size is from 30 to 200 μ m.

15. (original) A formulation as claimed in Claim 14 wherein the particle size is from 40 to 100 μ m.

16. (original) A formulation as claimed in Claim 10 wherein the microspheres are administered in an oleaginous carrier.

17. (cancelled)

18-20. (cancelled)

21. (previously presented) A formulation as claimed in claim 1 wherein the active ingredient is milled.

22. (original) A formulation as claimed in Claim 21 wherein the particle size is from 20 to 60 μ m.

23. (original) A formulation as claimed in Claim 22 wherein the particle size is from 5 to 20 μ m.

24-33. (cancelled)

34. (previously presented) A formulation comprising olanzapine pamoate monohydrate as an active ingredient, and one or more carriers.

35. (new) A formulation as claimed in claim 34 wherein the particle size of the olanzapine pamoate monohydrate is from about 20 to about 60 μ m.

36. (new) A formulation as claimed in claim 34 wherein the particle size of the olanzapine pamoate monohydrate is from about 5 to about 20 μ m.

37 (new) A formulation as claimed in 34 wherein said formulation has a prolonged sustained release of greater than 7 days and up to 30 days, and a burst release of less than 15% of the active ingredient.